The concordance rate of KRAS mutations in surgically resected tissue detected in liquid biopsy samples was more than 95%. Longitudinal monitoring of exoDNA provides unique predictive information on the outcome of neoadjuvant therapy in localized disease and in anticipating progression in the metastatic setting although the baseline CA19-9, exoDNA, and ctDNA cargo have a prognostic effect. Read more . . .